Insulin degludec/insulin aspart
Combination medication / From Wikipedia, the free encyclopedia
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[6][7][8][9] It contains insulin degludec and insulin aspart.[6] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[6]
Quick Facts Combination of, Clinical data ...
Combination of | |
---|---|
Insulin degludec | Long-acting human insulin analog |
Insulin aspart | Fast-acting human insulin analog |
Clinical data | |
Trade names | Ryzodeg |
AHFS/Drugs.com | Professional Drug Facts |
Pregnancy category | |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Close
The most frequently reported side effect is hypoglycemia (low blood glucose levels).[6]
It was approved for medical use in the European Union in January 2013,[6] and in Australia in November 2017.[2]